| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.089 | 0.07 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.059 | 0.07 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.07 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.072 | 0.07 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.07 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.073 | 0.07 |
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | 0.33 | 0.07 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.07 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.061 | 0.07 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.3 | 0.07 |